靶向T细胞发育药物研究进展  

Progress of Research on Drugs Targeting T Cell Development

作　　者：陈红[1,2] 胡洪波 CHEN Hong;HU Hongbo(Center for Immunology and Hematology Research,West China Hospital,Sichuan University,Chengdu 610041,China;State Key Laboratory of Biotherapy,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院免疫和血液中心,四川成都610041 [2]四川大学华西医院生物治疗国家重点实验室,四川成都610041

出　　处：《药学进展》2022年第8期631-640,共10页Progress in Pharmaceutical Sciences

基　　金：国家重点研发计划(No.2019YFA0110200);国家自然科学基金(No.82025002)。

摘　　要：T细胞是适应性免疫系统的主要组成部分,其发育和成熟在胸腺内完成。T细胞受体多样性是T细胞识别和应答多种抗原的重要基础,但胸腺在衰老过程中发生萎缩导致胸腺功能受损,初始T细胞输出减少。综述目前临床上使用的促进胸腺T细胞发育的药物的研究进展,以期为免疫功能受损患者恢复适应性免疫提供参考。T cells are the major players in adaptive immunity and thymus is the crucial organ for T cell development and maturation.The diversity of T cell receptors is an important basis for T cells to recognize and respond to diverse antigens,yet thymus undergoes agingrelated involution leading to impaired thymic function and decreased naïve T cell generation.This review summarizes the current progress of research on clinically used drugs promoting thymic T cell development,in order to provide reference for patients with impaired immune function to restore adaptive immunity.

关 键 词：T细胞受体 胸腺萎缩 T细胞再生 

分 类 号：R392.1[医药卫生—免疫学]